Last reviewed · How we verify
Domperidon
At a glance
| Generic name | Domperidon |
|---|---|
| Sponsor | Gadjah Mada University |
| Target | Aldehyde oxidase, Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Nausea and vomiting
Common side effects
Key clinical trials
- Compassionate Use of Domperidone for Refractory Gastroparesis (NA)
- Efficacy of Domperidone (a Prokinetic Agent) on Time in Range in Digestively Asymptomatic Type I Diabetic Patients With Delayed Gastric Emptying (Gastro-TIR) (PHASE3)
- Domperidone Expanded Access Treatment Program
- Domperidone in Treating Patients With Gastrointestinal Disorders (PHASE3)
- Domperidone and the Risk of Serious Adverse Events
- Treatment Use of Domperidone for Gastroparesis
- Preliminarily Evaluate the Efficacy of Domperidone in Adult Chinese Participants With Functional Dyspepsia (PHASE4)
- Apomorphine in Severe Brain-injured Patients (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Domperidon CI brief — competitive landscape report
- Domperidon updates RSS · CI watch RSS
- Gadjah Mada University portfolio CI